Raimondo Maria Pavarin, Loredana Lia, Stefano Tugnoli, Stefano Caracciolo
The relationship between cannabis use and suicidal behavior is complex, with no consensus in the literature. We used electronic health records of national health services to identify individuals who received a diagnosis of Cannabis Use Disorder in the Metropolitan area of Bologna from 2009 to 2019. In this cohort we identified accesses to Emergency Departments for suicide attempts from 2009 to 2019. The Crude Suicide Rate for 1,000 Person Years was 2.5, higher in females, in patients with Alcohol Use Disorders, with any psychiatric diagnosis, within one year from the first visit, and during the COVID-19 period...
November 27, 2023: Journal of Psychoactive Drugs
Morgan Hadley, Alicia Halliday, James M Stone
Hallucinogen Persisting Perception Disorder (HPPD) is considered rare in hallucinogen users although there are conflicting reports about its incidence and prevalence. HPPD may be more common in those with trait neuroticism. In this study, we invited hallucinogen and other drug users to complete an online questionnaire about their use of hallucinogens, their experience of HPPD symptoms, and their trait neuroticism and mental health symptoms. We received 802 responses with 415 of these containing adequate data for further analysis...
November 27, 2023: Journal of Psychoactive Drugs
Ekaterina V Fedorova, Allison Mitchel, Maddy Finkelstein, Janna Ataiants, Carolyn F Wong, Bridgid M Conn, Stephen E Lankenau
Cannabis was legalized for adult use in California in 2016 for individuals 21 and older. Among 18-20-years-olds, who can possess cannabis legally as medical cannabis patients (MCP) but not as non-patient cannabis users (NPU), the impact of adult use legalization (AUL) on cannabis and other substance use is unknown. Two cohorts of 18-20-year-old cannabis users (MCP and NPU) were surveyed, one in 2014-15 ( n  = 172 "pre-AUL") and another in 2019-20 ( n  = 139 "post-AUL"), using similar data collection methods in Los Angeles, California...
November 24, 2023: Journal of Psychoactive Drugs
Raminta Daniulaityte, Lance Ruhter, Charles Katz
Using the Arizona State Unintentional Drug Overdose Reporting System (AZ-SUDORS), the study aims to identify the social and drug characteristics of illicitly manufactured fentanyl (IMF)-related overdose deaths. The data include drug overdose deaths from July 1, 2019 to June 30, 2020. Decedents were categorized into four groups by types of opioids detected: (1) IMF-positive; (2) heroin-positive (negative for IMF); (3) pharmaceutical opioid-positive (negative for heroin or IMF); (4) nonopioid. Bivariate statistics were used to compare differences between IMF and other groups...
November 23, 2023: Journal of Psychoactive Drugs
Ana Cláudia Mesquita Garcia, Lucas Oliveira Maia, Everson Meireles, Denismar Alves Nogueira, Luís Fernando Tófoli
This study evaluated the psychometric properties of the Spiritual Well-Being Scale (SWBS) in a Brazilian sample. We analyzed spiritual well-being, defined as existential well-being (EWB) and religious well-being (RWB), among individuals with varying religious and spiritual experiences, both users and non-users of psychedelics. The online cross-sectional survey was conducted in Brazil, from April to June 2022. The psychometric analyses demonstrated reliability and validity based on the internal structure and the relationship with satisfactory external variables concerning the RWB and EWB factors of the SWBS...
November 16, 2023: Journal of Psychoactive Drugs
Anees Bahji, Isis Lunsky, Gilmar Gutierrez, Gustavo Vazquez
There has been a resurgence in psychedelic research for managing psychiatric conditions in recent years. This study aimed to present a comprehensive review of the current state of the field by applying a systematic search strategy for articles on the effectiveness and tolerability of four psychedelic-assisted therapies (psilocybin, lysergic acid diethylamide [LSD], 3,4-Methylenedioxymethamphetamine [MDMA], and ayahuasca) for adults with symptoms of depression, anxiety, and posttraumatic stress disorder (PTSD)...
November 15, 2023: Journal of Psychoactive Drugs
A Wirsching, T Bostoen, A C Huizink
In the Netherlands, scientific interest in psychedelics and their subjective effects has been increasing. The present study examined the reliability, construct and predictive validity of the Dutch 30-item Revised Mystical Experience Questionnaire (MEQ30), a self-report measure that has been used to assess subjective and mystical experiences occasioned by psychedelics. In an online survey, 322 Dutch-speaking adults retrospectively reported on profound experiences with psychedelics. Confirmatory factor analyses demonstrated that both a four-factor structure and the same model extended with the MEQ30-total score as a second-order latent variable fit the data...
November 15, 2023: Journal of Psychoactive Drugs
Catherine D Trinh, Melissa R Schick, Blaine Lynch-Gadaleta, Anika Martz, Tessa Nalven, Nichea S Spillane
Young adults exhibit high rates of cannabis use and are at heightened risk of experiencing negative cannabis-associated consequences. The purpose of the present study was to replicate and extend to prior work on savoring, the ability to experience positive experiences/emotions, and cannabis use frequency on cannabis-associated consequences. Young adults (18-25 years old, N  = 122, 36.1% women) who reported weekly cannabis use completed self-report surveys. Savoring was significantly associated with cannabis use frequency ( r  = ...
November 10, 2023: Journal of Psychoactive Drugs
Maria Helha Fernandes-Nascimento, André Brooking Negrão, Karine Viana-Ferreira, Bruno Daniel Rasmussen Chaves, Wang Yuan-Pang
Ibogaine is a natural psychoactive drug that has been investigated for its potential role in the treatment of substance use disorders since the mid-1960s. To evaluate the interest in ibogaine's use as a therapeutic agent, we performed a scientometric analysis covering the last three decades (1993-2002, 2003-2012, and 2013-2022). A complementary analysis was performed to select and describe published clinical trials and meta-analyses. A total of 1523 references were found. Linear growth of publications in the first and third decades were identified, and the average number of publications from 1993 to 2002 was lower than that in the other two decades...
November 6, 2023: Journal of Psychoactive Drugs
Marija Franka Žuljević, Antonija Mijatović, Stjepan Ljudevit Marušić, Gunnar Kudrjavets, Ivan Buljan, Darko Hren
Analyzing online retrospective experience reports of psychedelic use can provide valuable insight into their acute subjective effects. Such reports are unexplored in relation to mystical states, which are thought to be a therapeutic mechanism within psychedelic-assisted psychotherapy. We created a set of words that, when encountered in an experience report, indicate the occurrence of mystical elements within the experience. We used the website to retrieve 7317 publicly available retrospective psychedelic experience reports of psychedelic use, primarily of psilocybin, and have a designated experience intensity level self-assessed by the text authors during submission of the report...
November 3, 2023: Journal of Psychoactive Drugs
Jakub Greń, Krzysztof Ostaszewski, Matthew R Pearson
Resiliency theory might provide a conceptual framework for understanding why adverse substance-related consequences vary considerably among young adults using psychoactive substances. Protective behavioral strategies (PBS) are behaviors that reduce substance use and related consequences. Despite such suggestions, to date no research has explicitly treated PBS as resilience factors. The purpose of this study was to examine compensatory and protective models of resilience among young adults using various substances...
October 24, 2023: Journal of Psychoactive Drugs
Veronica Magar, Julian Urrutia, Brian T Anderson
The global prevalence of substance abuse and mental disorders continues to challenge healthcare systems, with one in eight individuals affected. The therapeutic potential of psychedelics is recognized not only for treating mental disorders but also for enhancing well-being and promoting pro-social behaviors. Conventional biomedical research models fall short in addressing the broader health needs of populations and poorly suited for overcoming barriers to service delivery. This special issue includes six articles that explore alternative approaches to psychedelic research and practice, emphasizing collaboration with diverse actors, including indigenous communities, and incorporating traditional knowledge systems into contemporary psychedelic research...
October 16, 2023: Journal of Psychoactive Drugs
Kiffer G Card, Ashmita Grewal, Kalysha Closson, Gina Martin, Laura Baracaldo, Sandra Allison, Daniel J Kruger, Zach Walsh
Survivors of adverse childhood experience are at elevated risk for psychological distress. In recent years, renewed interest in psychedelic medicine has highlighted the therapeutic potential of psilocybin for those who have experienced childhood adversity. However, recreational psilocybin use remains illegal and access to approved therapies is difficult. Such use provides an opportunity to explore the therapeutic potential of psilocybin for psychological distress among people with adverse childhood experiences...
October 10, 2023: Journal of Psychoactive Drugs
Ismael Apud, Juan Scuro, Luisina Rodríguez, Gonzalo Hernandez, Ignacio Carrera, Frank Lozano, Juan Ignacio Retta
This study is an interdisciplinary research into Uruguayan ayahuasca users belonging to one neo-shamanic and one Santo Daime group. The study involved the chemical analysis of ayahuasca samples, an ethnographic description of the two traditions and rituals, and the application of psychometric scales to measure personality differences, and the acute psychological effects during an ayahuasca ritual. Personality measurements showed lower scores for Santo Daime in Neuroticism-Anxiety, Dependence, Low Self-Esteem, Anger and Restlessness...
September 25, 2023: Journal of Psychoactive Drugs
Julian Urrutia, Brian T Anderson, Sean J Belouin, Ann Berger, Roland R Griffiths, Charles S Grob, Jack E Henningfield, Beatriz C Labate, Larissa J Maier, M Catherine Maternowska, Frank Weichold, David B Yaden, Veronica Magar
As individuals and communities around the world confront mounting physical, psychological, and social threats, three complimentary mind-body-spirit pathways toward health, wellbeing, and human flourishing remain underappreciated within conventional practice among the biomedical, public health, and policy communities. This paper reviews literature on psychedelic science, contemplative practices, and Indigenous and other traditional knowledge systems to make the case that combining them in integrative models of care delivered through community-based approaches backed by strong and accountable health systems could prove transformative for global health...
September 25, 2023: Journal of Psychoactive Drugs
Emmy Manson, Erin Ryding, Wes Taylor, Gail Peekeekoot, Sara G Gloeckler, Pearl Allard, Charsanaa Johnny, Kyle T Greenway, Shannon Dames
Novel and traditional psychedelic medicines are attracting interest as potential treatments of mental illness. Before psychedelic therapies can be made available in culturally safe and effective ways to diverse peoples, the field must grapple with the complex legacies of colonialism and ongoing clashes between biomedical and Indigenous Ways of Knowing. This article presents results of a pilot program offering group-based therapy augmented by three sessions of ketamine at a psychedelic dose, for a group of Indigenous participants...
September 18, 2023: Journal of Psychoactive Drugs
Robin A Thompson, David Johnson, Melanie Whitter, Madison Ashworth, Ernest Fletcher
Single State Agencies (SSAs) are responsible for managing the publicly funded alcohol and other drug prevention, treatment, and recovery service system. Recovery housing (RH) is an important recovery support service (RSS) for individuals experiencing substance use disorder (SUD). Despite its effectiveness, information on state utilization and support is limited. To assess state-level support for RH and its incorporation within the SSA-managed SUD service systems, we administered a survey with SSAs in the 50 United States and the District of Columbia...
September 18, 2023: Journal of Psychoactive Drugs
Elisabeth Prevete, Valeria Catalani, Darshan Singh, Kim P C Kuypers, Eef L Theunissen, Honor D Townshend, Hani Banayoti, Johannes G Ramaekers, Massimo Pasquini, Ornella Corazza
In recent years, the online sale of kratom ( Mitragyna speciosa ), a Southeast Asian plant with both medicinal and psychoactive properties, has raised health concerns mainly due to the uncontrolled diffusion of adulterated kratom-related products. This exploratory study provides, for the first time, a snapshot of the availability of kratom products on the darknet which has been further validated by data searches on the surface web. A total of 231 listings of kratom across 23 darknet marketplaces were identified between March 2020 and October 2021...
September 13, 2023: Journal of Psychoactive Drugs
Marianna Graziosi, Manvir Singh, Sandeep M Nayak, David B Yaden
Reports of psychedelic experiences may contain similarities and differences across cultural contexts, but most current characterizations and quantifications of psychedelic experiences come from Western medical and naturalistic settings. In this article, we begin with a brief history of the diversity of psychedelic use in non-Western settings. We then compare and contrast accounts of psychedelic experiences within and beyond Western, educated, industrialized, rich, and democratic (WEIRD) contexts. We focus on specific reports of direct testimony of the acute subjective effects of psychedelics experienced across these contexts...
September 7, 2023: Journal of Psychoactive Drugs
Anja Loizaga-Velder, Cecile Giovannetti, Ricardo Campoy Gomez, Teresa Eduwiges Castillo Valenzuela, Gloria Rachel Ochoa Jaime, Gabrielle Agin-Liebes, Olivia Marcus, Brian Rush
This paper describes three case studies from an outpatient intercultural therapeutic program founded and run by Yaqui health professionals and traditional healers to serve members of the Yaqui tribe residing in Sonora, Mexico. This pilot therapeutic program has been designed specifically for Indigenous individuals, incorporating the ceremonial use of naturally derived psychedelics in addressing substance use disorders and other mental health issues. The program employs a community-based approach, integrating various traditional Indigenous healing practices like the sweatlodge ( temazcal ), medicinal plant preparations, and the ritualistic use of selected psychedelics from natural sources (such as ayahuasca, peyote, and secretions from Incilius alvarius )...
September 7, 2023: Journal of Psychoactive Drugs
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.